<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11861127</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.781</article-id><article-id pub-id-type="other">EPP0700</article-id><article-id pub-id-type="pii">S0924933824007818</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Influence of Ovocystatin on A&#x003b2;42 soluble oligomeric and fibril formation in in vitro studies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sta&#x00144;czykiewicz</surname><given-names>B.</given-names></name><xref rid="aff1860" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0642" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Piksa</surname><given-names>M.</given-names></name><xref rid="aff1861" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Goszczy&#x00144;ski</surname><given-names>T.</given-names></name><xref rid="aff1862" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Go&#x00142;&#x00105;b</surname><given-names>K.</given-names></name><xref rid="aff1863" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Konopska</surname><given-names>B.</given-names></name><xref rid="aff1863" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zab&#x00142;ocka</surname><given-names>A.</given-names></name><xref rid="aff1861" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff1860"><sup>1</sup>Department of Psychiatry, <institution>Wroclaw Medical University</institution></aff><aff id="aff1861"><sup>2</sup>Department of Microbiology</aff><aff id="aff1862"><sup>3</sup>Department of Experimental Oncology, <institution>Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences</institution></aff><aff id="aff1863"><sup>4</sup>Department of Pharmaceutical Biochemistry, <institution>Wroclaw Medical University</institution>, <city>Wroclaw</city>, <country>Poland</country></aff><author-notes><corresp id="cor0642"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="756">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S380</fpage><lpage>S380</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824007818a.pdf"/><abstract><sec id="sec3859"><title>Introduction</title><p>Alzheimer&#x02019;s disease is characterized by the presence of &#x003b2;-amyloid deposits in senile plaques and brain vessels. &#x003b2;-amyloid stimulates the glial release of proinflammatory cytokines, reactive oxygen species (ROS), or nitric oxide (NO), which are potentially toxic to neurons. One potential therapy for Alzheimer&#x02019;s disease is the use of agents that inhibit the aggregation and formation of insoluble &#x003b2;-amyloid deposits in the brain, or break down the aggregates that have already formed, thus preventing their toxicity.</p></sec><sec id="sec3860"><title>Objectives</title><p>This study aimed to evaluate the effect of ovocystatin on the formation and destabilization of &#x003b2;-amyloid aggregation.</p></sec><sec id="sec3861"><title>Methods</title><p>The effect of ovocystatin on &#x003b2;-amyloid aggregation was determined by Thioflavin T (ThT) Assay and Transmission Electron Microscopy (TEM). The impact on PC12 cell viability was determined by MTT assay.</p></sec><sec id="sec3862"><title>Results</title><p>Ovocystatin can interact directly with A&#x003b2;<sub>42</sub>, inhibiting its aggregation and reducing the toxicity induced by aggregated forms of &#x003b2;-amyloid. All effects are dose-dependent. Additionally, a significant increase in the PC12 cell viability treated simultaneously with A&#x003b2;<sub>42</sub> and ovocystatin was observed.</p></sec><sec id="sec3863"><title>Conclusions</title><p>Ovocystatin may be an important factor in the prevention and treatment of Alzheimer&#x02019;s disease by regulating the conversion of monomeric &#x003b2;-amyloid into larger and potentially more toxic particles. However, the mechanisms of inhibition of amyloid fibrillar protein formation and/or destabilization by ovocystatin are still unclear and require further investigation.</p></sec><sec id="sec3864"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>